Astrazeneca plc
Research Astrazeneca plc (AZN) on Bullrun: valuation model: 28.9% overvalued, market cap USD 263.12B, P/E 51.0, dividend yield 1.3%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerAZN
- ExchangeNASDAQ
- CountryUnited Kingdom
- SectorHealthcare
- IndustryDrug Manufacturers-General
- CurrencyUSD
- Valuation signal28.9% overvalued
- Market capUSD 263.12B
- P/E51.0
- Dividend yield1.3%
- Financial periodQ2 2026
- RevenueUSD 15.38B
- Net incomeUSD 2.51B
- Free cash flow-USD 240.00M
- Gross margin83.6%
Valuation Snapshot
Bullrun's latest valuation model marks Astrazeneca plc as 28.9% overvalued; latest market cap is USD 263.12B; P/E is 51.0; dividend yield is 1.3%.
Peer valuation comparison
Latest P/E is 50.95x versus a Healthcare sector median of 24.46x (108.3% above).
Latest dividend yield is 1.31% versus a Healthcare sector median of 2.11% (37.9% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 58.74B | USD 10.23B | USD 8.67B | 81.9% | 5.74 | USD 5.71B | USD 29.62B | USD 48.67B |
| FY2024 | USD 54.07B | USD 7.04B | USD 7.28B | 81.1% | 3.19 | USD 5.49B | USD 30.11B | USD 40.79B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 263.12B | 51.0 | 1.3% | 2.15 |
| 2025 | 2025-12-31 | USD 285.12B | 56.1 | 1.7% | 3.13 |
| 2024 | 2024-12-31 | USD 203.13B | 58.2 | 2.3% | 2.97 |
| 2023 | 2023-12-29 | USD 208.78B | 71.3 | 2.2% | 2.9 |
| 2022 | 2022-12-30 | USD 210.12B | 208.6 | 2.1% | 2.9 |
| 2021 | 2021-12-31 | USD 180.51B | 832.1 | 2.4% | 2.8 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 2.15 USD, yield 1.3%.
About Astrazeneca plc
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.
Related stock research
Other Healthcare stocks
Frequently asked questions
Is Astrazeneca plc overvalued or undervalued?
Bullrun's valuation model currently marks Astrazeneca plc as 28.9% overvalued.
What is Astrazeneca plc's market cap?
Astrazeneca plc's market capitalization is USD 263.12B.
What is Astrazeneca plc's P/E ratio?
Astrazeneca plc's price-to-earnings (P/E) ratio is 51.0.
Does Astrazeneca plc pay a dividend?
Astrazeneca plc has a dividend yield of 1.3%.
What does Astrazeneca plc do?
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.